BridgeBio Pharma, Inc. Common Stock
BBIOBridgeBio Pharma, Inc. is a biotechnology company focused on discovering, developing, and delivering treatments for genetic diseases and cancers. Founded in 2015, the company aims to address underserved patient populations by advancing innovative therapies from research to commercialization.
Company News
The biotech sector rebounded strongly in 2025 as M&A activity surged, becoming a stabilizing force for small and mid-cap companies. With 57% of biopharma acquisitions involving smaller firms and $30.9 billion in deals, investor sentiment shifted from GLP-1 drugs toward cancer and autoimmune disease treatments, particularly next-generation CAR-T t...
BridgeBio Pharma presented data from the ATTRibute-CM study showing acoramidis significantly reduces all-cause mortality in variant ATTR-CM populations, with a 69% risk reduction in mortality for patients with the V142I genetic variant.
The National Advertising Division will refer BridgeBio Pharma to government agencies after the company failed to participate in an NAD inquiry regarding claims about its Attruby medication's superiority over Pfizer's Vyndamax.
BridgeBio Pharma announced successful Phase 3 trial results for BBP-418, a potential treatment for limb-girdle muscular dystrophy type 2I/R9, showing significant improvements in muscle function, glycosylation, and reduced muscle damage markers.
BridgeBio Pharma presented data from the ATTRibute-CM study showing acoramidis reduces cardiovascular outcomes in ATTR-CM patients, with significant risk reduction observed as early as the first month of treatment and sustained through 30 months.
